Department of Pharmaceutical Sciences, Josai International University, Togane City, Chiba, Japan.
Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02371-17. Print 2018 May.
Ceftazidime-avibactam is a "second-generation" β-lactam-β-lactamase inhibitor combination that is effective against expressing class A extended-spectrum β-lactamases, class A carbapenemases, and/or class C cephalosporinases. Knowledge of the interactions of avibactam, a diazabicyclooctane with different β-lactamases, is required to anticipate future resistance threats. FOX family β-lactamases possess unique hydrolytic properties with a broadened substrate profile to include cephamycins, partly as a result of an isoleucine at position 346, instead of the conserved asparagine found in most AmpCs. Interestingly, a single amino acid substitution at N346 in the AmpC is implicated in resistance to the aztreonam-avibactam combination. In order to understand how diverse active-site topologies affect avibactam inhibition, we tested a panel of clinical isolates producing using ceftazidime-avibactam, determined the biochemical parameters for inhibition using the FOX-4 variant, and probed the atomic structure of avibactam with FOX-4. Avibactam restored susceptibility to ceftazidime for most isolates producing ; two isolates, one expressing and the other producing , displayed an MIC of 16 μg/ml for the combination. FOX-4 possessed a / value of 1,800 ± 100 M · s and an off rate () of 0.0013 ± 0.0003 s Mass spectrometry showed that the FOX-4-avibactam complex did not undergo chemical modification for 24 h. Analysis of the crystal structure of FOX-4 with avibactam at a 1.5-Å resolution revealed a unique characteristic of this AmpC β-lactamase. Unlike in the -derived cephalosporinase 1 (PDC-1)-avibactam crystal structure, interactions (e.g., hydrogen bonding) between avibactam and position I346 in FOX-4 are not evident. Furthermore, another residue is not observed to be close enough to compensate for the loss of these critical hydrogen-bonding interactions. This observation supports findings from the inhibition analysis of FOX-4; FOX-4 possessed the highest (dissociation constant) value (1,600 nM) for avibactam compared to other AmpCs (7 to 660 nM). Medicinal chemists must consider the properties of extended-spectrum AmpCs, such as the FOX β-lactamases, for the design of future diazabicyclooctanes.
头孢他啶-阿维巴坦是一种“第二代”β-内酰胺-酶抑制剂组合,对表达类 A 型扩展谱β-内酰胺酶、类 A 型碳青霉烯酶和/或类 C 型头孢菌素酶的具有活性。为了预测未来的耐药威胁,需要了解阿维巴坦与不同β-内酰胺酶的相互作用,阿维巴坦是一种二氮杂二环辛烷,具有不同的β-内酰胺酶水解特性和更广泛的底物谱,包括头孢菌素,部分原因是 346 位的异亮氨酸,而不是大多数 AmpC 中发现的保守天冬酰胺。有趣的是,AmpC 中的 346 位单个氨基酸取代与氨曲南-阿维巴坦组合的耐药性有关。为了了解不同的活性位点拓扑结构如何影响阿维巴坦的抑制作用,我们使用头孢他啶-阿维巴坦测试了一组产生的临床分离株,使用 FOX-4 变体确定了抑制的生化参数,并利用 FOX-4 探测了阿维巴坦的原子结构。阿维巴坦使大多数产生的分离株对头孢他啶的敏感性恢复;两种分离株,一种表达 ,另一种产生 ,对该组合的 MIC 为 16μg/ml。FOX-4 的 值为 1800±100M·s, 为 0.0013±0.0003s。质谱显示,24 小时内 FOX-4-阿维巴坦复合物未发生化学修饰。在 1.5-Å分辨率下分析 FOX-4 与阿维巴坦的晶体结构揭示了这种 AmpC β-内酰胺酶的一个独特特征。与来源于头孢菌素酶 1(PDC-1)的阿维巴坦晶体结构不同,阿维巴坦与 FOX-4 中的位置 I346 之间的相互作用(例如氢键)不明显。此外,没有观察到另一个残基足够接近以弥补这些关键氢键相互作用的缺失。这一观察结果支持 FOX-4 抑制分析的结果;与其他 AmpC(7 至 660 nM)相比,FOX-4 对阿维巴坦的 值(解离常数)最高(1600 nM)。药物化学家在设计未来的二氮杂二环辛烷时,必须考虑到扩展谱 AmpC 的特性,如 FOX β-内酰胺酶。